Genflow Biosciences Plc (GB:GENF) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Genflow Biosciences Plc has secured €4 million in non-dilutive funding from the Wallonia region to advance its gene therapy, GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). This financial boost includes a research grant and a repayable advance, covering substantial development costs and marking a significant step forward for the company. The support underscores the innovation and potential of Genflow’s approach in an area with limited treatment options.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
